Researchers are exploring the use of small-molecule degraders to target oncogenic KRAS, a protein implicated in certain cancers. These degraders, which may utilize various approaches such as proteomimetic polymers or PROTAC technology, aim to selectively degrade KRAS and other related proteins like MYC. The effectiveness of these small molecules is being investigated in preclinical studies, with some reports suggesting potential against certain KRAS mutant cancers.